FDA Fast-Tracks Psychedelics — Kalshi Market Prices Approval Odds

- The FDA will issue priority review vouchers for three psychedelics starting April 21, cutting review timelines from months to weeks.

- Kalshi's psychedelic approval contract trades around 51 cents, implying a coin-flip chance the FDA greenlights a psychedelic before 2027.

- Watch for Compass Pathways' psilocybin application to advance first, with HHS Secretary RFK Jr. pushing for approval within 12 months.

The FDA is handing out national priority review vouchers to three psychedelic substances starting the week of April 21, 2026. Commissioner Marty Makary said the vouchers can compress review timelines from several months to just weeks. No psychedelic has ever received FDA approval in the United States. The agency rejected MDMA for PTSD in 2024, and ibogaine has never even undergone U.S. human trials. But the political winds appear to be shifting fast, suggesting the landscape could look very different in the near term. HHS Secretary RFK Jr. told the House Energy and Commerce Committee he hopes a psychedelic pharmaceutical gets approved within 12 months. The FDA also hired Mike Davis, former chief medical officer of the Usona Institute, as deputy director of its drug evaluation center. Trump signed an executive order directing at least $50 million to states advancing psychedelic programs. The order also mandates expedited rescheduling for any psychedelic that clears FDA approval.

KXFDAAPPROVALPSYCHEDELIC-27-ANYPSYCH is trading around 51 cents, giving any psychedelic roughly even odds of FDA approval before January 1, 2027. Compass Pathways' psilocybin contract for approval before 2028 shows a wider 10-cent spread, bid at 61 cents and offered at 71 cents. That gap suggests traders are less certain about a specific company timeline even as broader optimism builds.

The priority vouchers rolling out the week of April 21 could serve as the immediate catalyst, suggesting renewed buying momentum may be on the horizon. If the FDA assigns one to Compass Pathways' psilocybin therapy, expect the Compass-specific contract—currently around 61c bid / 71c ask—to jump sharply toward par or higher. Conversely, if the vouchers go only to early-stage compounds that have not yet completed Phase 3 trials—such as ibogaine, which has never undergone human clinical trials in the U.S.—the contract could slide back toward the low 40-cent range, similar to the Compass Pathways July 2027 contract, which carries a YES bid of 42c and YES ask of 48c. Experts emphasize that standard clinical requirements still apply, suggesting that political enthusiasm alone may not be sufficient to alter established regulatory benchmarks.